drugset / Trial / NCT00830427

A Study To Examine The Safety And Efficacy Of PF-00610355 In Moderately Asthmatic Subjects

NCT00830427

Phase 2 Withdrawn Pfizer
RandomizedParallel-groupSingle-blindTreatment

Summary

This study (A7881006) is the first multiple dose study in moderate asthmatic subjects and aims to determine the safety and efficacy of PF-00610355 when subjects take PF-00610355 on a daily basis for 4 weeks in subjects maintained on inhaled corticosteroid.

Timeline

Start
2009-04-15
Primary completion
2009-12-31
Completion
2009-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject PF-00610355 Small molecule 100 ug Inhaled
Subject PF-00610355 Small molecule 300 ug Inhaled
Subject PF-00610355 Small molecule 600 ug Inhaled